Approximately 40% of women of recommended age for mammography screening have dense breasts. Dense breast tissue may obscure cancers on a mammogram and recent research indicates it is the leading common risk factor for development of breast cancer. More than 70% of breast cancers occur in women with dense breasts, and research has shown that nearly one in two cancers is missed on standard mammography in extremely dense breasts. Because of the limitations of screening mammography, supplemental imaging such as 3D automated breast ultrasound (ABUS) is being used to improve screening outcomes by improving detection of early invasive cancers and decreasing interval cancer rates.
Results from multiple large-scale screening ultrasound studies involving thousands of women demonstrate that automated breast ultrasound improves cancer detection as a supplement to mammography. The EASY Study (European Asymptomatic Screening Study) study published in European Journal of Radiology shows that it is feasible to implement 3D ABUS into a high-volume mammography center and increase the cancer detection rate while maintaining a low recall rate well within the recommendations of the European guidelines for quality assurance in breast cancer screening and diagnosis. This is very consistent with the results of the SomoInsight study by Brem et al., published in Radiology, and the reader performance studies by Skaane et al., published in Acta Radiologica, and Giger et al., published in the American Journal of Roentgenology. All three studies concluded that adding 3D ABUS to mammography improved the performance of breast screening.
GE Healthcare is the sole provider of FDA-approved ultrasound technology designed for screening women with dense breast tissue, and is also CE marked for screening women with dense breasts and diagnostic ultrasound imaging of breasts in symptomatic women. Engineered for automated breast ultrasound screening, the Invenia ABUS system helps to overcome the limitations of traditional ultrasound making it well-suited to address the specific workflow requirements for high-volume breast cancer screening environments. Invenia ABUS has been proven to find a 57% relative increase in invasive cancer over mammography alone, and has both a screening and a diagnostic indication for use. Besides increased detection, the system is designed for reproducibility, ease of use, and both patient and operator comfort.